Abstract
DNA sequencing-based measurable residual disease (MRD) detection has shown to be clinically relevant in AML. However, the same methodology cannot be applied to fusion gene-driven subtypes of AML such as core-binding factor AML (CBF-AML). Here in this study, we evaluated the effectiveness of using DNA and RNA sequencing in MRD detection and in tracking clonal dynamics in CBF-AML. Using RNA-seq, we were able to quantify expression levels of RUNX1-RUNX1T1 and CBFB-MYH11 at diagnosis and their levels of reduction during remission (P < 6.3e-05 and P < 2.2e-13). The level of reduction of RUNX1-RUNX1T1 as measured by RNA-seq and qPCR were highly correlated (R2 = 0.74, P < 5.4e-05). A decision tree analysis, based on 3-log reduction of RUNX1-RUNX1T1 and cKIT-D816mut at diagnosis, stratified RUNX1-RUNX1T1 AML patients into three subgroups. These three subgroups had 2-year overall survival rates at 87%, 74%, and 33% (P < 0.08) and 2-year relapse incidence rates at 13%, 42%, and 67% (P < 0.05). On the other hand, although low residual allelic burden was common, it was not associated with long-term outcome, indicating that mutation clearance alone cannot be interpreted as MRD-negative. Overall, our study demonstrates that the clinical util...Continue Reading
References
Dec 11, 1999·Nucleic Acids Research·M Kanehisa, S Goto
Jul 3, 2002·Nature Reviews. Cancer·Nancy A Speck, D Gary Gilliland
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Mar 18, 2011·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collab
Aug 10, 2012·Blood·John A Liu YinAlan K Burnett
Dec 5, 2012·Bone Marrow Transplantation·Y Kanda
Jan 17, 2013·Blood·Eric JourdanUNKNOWN French AML Intergroup
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Sep 28, 2014·Bioinformatics·Simon AndersWolfgang Huber
Dec 18, 2014·Genome Biology·Michael I LoveSimon Anders
Aug 26, 2015·JAMA : the Journal of the American Medical Association·Jeffery M KlcoTimothy J Ley
Oct 2, 2015·Leukemia·T KimD D Kim
Dec 5, 2015·Haematologica·Christophe WillekensUNKNOWN French AML Intergroup
Mar 13, 2016·Blood·Vincent-Philippe LavalléeJosée Hébert
Mar 17, 2016·Blood·Nicolas DuployezClaude Preudhomme
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Nov 1, 2016·Nature Genetics·Zachary J FaberJames R Downing
Nov 16, 2016·Leukemia·A-K EisfeldC D Bloomfield
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Jul 9, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellNdiya Ogba
Mar 31, 2018·The New England Journal of Medicine·Mojca Jongen-LavrencicPeter J M Valk
Apr 28, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kiyomi MoritaKoichi Takahashi
Aug 16, 2018·Blood·TaeHyung KimDennis Dong Hwan Kim
Sep 2, 2018·Haematologica·Laura W DillonChristopher S Hourigan
Sep 8, 2018·Blood·Felicitas TholMichael Heuser